Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514296 | 1.00 | TDP1 (0.49) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL19065174 | 1.00 | TDP1 (0.49) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL29679276 | 0.95 | FOLH1 (0.46) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL19079056 | 0.94 | TDP1 (0.44) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL29679161 | 0.92 | TDP1 (0.42) | TDP1PAX8MAPTNPSR1 | |
| SCHEMBL29679269 | 0.92 | CA1 (0.42) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL29598511 | 0.91 | FOLH1 (0.48) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL29679077 | 0.91 | FNTA (0.42) | TDP1PAX8FOLH1 | |
| SCHEMBL31514305 | 0.91 | PLG (0.43) | TDP1PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL29679162 | 0.91 | MMP1 (0.45) | TDP1PAX8MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025095479-A1 | NOVEL PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGAND AND USE THEREOF | 서울대학교병원 | 2025-05-08 | — | — | WO | disclosed |
| CN-108541302-B | Urea-based Prostate Specific Membrane Antigen (PSMA) inhibitors for imaging and therapy | 五一一制药股份有限公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-3397968-B1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | TDP1 4743/4885PAX8 3373/4885MEN1 411/4885 |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | KLK3, FOLH1, UTS2R | TDP1 4743/4885PAX8 3373/4885MEN1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.